Loading
A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.
Approved 1963. Component of CHOP, ABVD-era regimens, ALL induction/maintenance, VAC/VDC (rhabdomyosarcoma, Ewing), Wilms tumour (VA/DD-4A), neuroblastoma and medulloblastoma regimens, EMA-CO. Fatal if given intrathecally; vincristine shortages (2019) disrupted paediatric care. Liposomal vincristine (Marqibo, 2012) for Ph-negative ALL was discontinued 2022.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Binds β-tubulin and prevents microtubule polymerisation, arresting mitosis; dose-limited by peripheral neuropathy.
1.Vincristine slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic; Marqibo (liposomal) was discontinued.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: vincristine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Adults with Philadelphia (PH) chromosome negative (-) ALL in second relapse or greater relapsed or whose disease has progressed following 2 or greater treatment lines of anti-leukemia therapies
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Adults with Philadelphia (PH) chromosome negative (-) ALL in second relapse or greater relapsed or whose disease has progressed following 2 or greater treatment lines of anti-leukemia therapies
Withdrawn: the indication came off the label 9.7 years after its accelerated approval.
| Region | Year | Indication |
|---|---|---|
| US | 1963 | Acute leukaemia; Hodgkin and non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms tumour |
Read for the class this product belongs to (vinca alkaloids) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
POLARIX gave the first new first-line standard for DLBCL since rituximab was added to CHOP, and pola-R-CHP is now approved and widely used, especially in higher-risk or ABC-type disease. The gain is modest and survival is unchanged, so many clinicians still use R-CHOP in lower-risk or GCB-type patients. Cost and subgroup uncertainty drive ongoing debate.
Paclitaxel with antiretroviral therapy is the treatment to supply for advanced AIDS-associated Kaposi sarcoma in resource-limited settings; cheaper regimens are inferior.
R-CHOP remains the standard first-line regimen for diffuse large B-cell lymphoma. The trial is also the clearest lesson in the disease about adopting a regimen on single-arm data: dose-adjusted EPOCH-R had been used widely for a decade before this comparison existed.
Four cycles rather than six for young patients with limited-stage, low-risk aggressive B-cell lymphoma. The saving is two cycles of anthracycline and vincristine in people who will live for decades afterwards.
Confirmation, by a different route from HD18, that the interim scan can safely direct de-escalation in advanced Hodgkin lymphoma, and that most of the toxicity of escalated BEACOPP can be avoided in the 84 per cent of patients who respond early.
A failure worth reading: the drug worked where patients could tolerate the regimen it was added to, and harmed where they could not. It is the strongest argument in lymphoma for designing first-line combinations around what an older patient can finish.
The evidence that early follicular lymphoma is less often confined to the radiation field than staging suggests, and that a short course of systemic treatment after radiotherapy reduces relapse. It is also the reason modern practice stages this disease with positron emission tomography.
Query for this drug: (TITLE:"Vincristine" OR ABSTRACT:"Vincristine" OR TITLE:"Oncovin" OR ABSTRACT:"Oncovin" OR TITLE:"Marqibo" OR ABSTRACT:"Marqibo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vincristine, not a curated reading list.
Shares A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss, Erythropoietin for Management of Anemia Caused by Chemotherapy, Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype, EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients and the tags generic, who-essential.
Shares ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, ACTG A5263/AMC 066, Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma and the tags generic, who-essential.
Shares EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, Donald Pinkel, Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents, Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma) and the tags generic, who-essential.
Shares COG AREN0532, EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups), FOXO1 fusion status and IRS group (rhabdomyosarcoma) and the tags generic, who-essential.
Shares Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667), Vindesine, Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma, AHL2011 and the tags generic, who-essential.
Shares ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, ACTG A5263/AMC 066, AHOD1331, AHL2011 and the tags generic, who-essential.
Shares FOXO1 fusion status and IRS group (rhabdomyosarcoma), High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN), Hepatoblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH) and the tags generic, who-essential.
Shares Small-molecule API synthesis, Peripheral neuropathy (chemotherapy-induced), Nerve damage from chemotherapy: what recovers, and what helps, Generic sterile injectables (the 2023 platinum shortage) and the tags generic, who-essential.